RxDoctor Payments Data

Raman Ashta, MD

Family Medicine · Melbourne, FLNPI 1144496993

Payments from drug & device makers

$2,489in general payments, 2019–2025

Across 113 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$499
  • Pfizer$249
  • Lilly USA, LLC$238
  • Astellas Pharma US Inc$212
  • AstraZeneca$189
  • AbbVie$185
  • plus $917 from 16 others

What the payments were for

  • Food & beverage$2,30092%
  • Education$1898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,489 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$173,583
Medicare patients
350
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$126,626
MounjaroTirzepatide70$88,480
EliquisApixaban82$75,837
JardianceEmpagliflozin72$73,535
TrulicityDulaglutide32$47,405
XareltoRivaroxaban53$35,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$33,377
FarxigaDapagliflozin Propanediol17$23,273
WegovySemaglutide11$14,217
Praluent PenAlirocumab27$13,594
Repatha SureclickEvolocumab11$13,306
JanuviaSitagliptin Phosphate22$13,004
Arnuity ElliptaFluticasone Furoate15$6,488
Atorvastatin Calcium527$5,998
SynthroidLevothyroxine Sodium51$4,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$499$140,84295 claims
Lilly USA, LLCMounjaro, Trulicity$238$135,886102 claims
PfizerEliquis, Paxlovid$249$77,266106 claims
GSKTrelegy Ellipta, Arnuity Ellipta$37$39,86561 claims
AstraZenecaFarxiga$189$23,27317 claims
AbbVieSynthroid$185$4,95051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →